<DOC>
	<DOCNO>NCT00659711</DOCNO>
	<brief_summary>Sitagliptin new oral hypoglycemic anti-diabetic drug use either alone combination metformin thiazolidinedione control type 2 diabetes mellitus . Sitagliptin show few side effect control blood glucose value . Obesity diabetes state increase inflammation influence free radical inflammatory marker ( chemical blood increase due inflammation body ) also major risk factor atherosclerotic disease . In study want see effect sitagliptin marker . We believe Sitagliptin may exert anti-inflammatory effect human . The purpose study determine addition sitagliptin diabetic patient provide added benefit . We believe sitagliptin provide added benefit suppress free radical ( charge substance cause damage body ) inflammation .</brief_summary>
	<brief_title>The Effect Januvia ( Sitagliptin ) Oxidative Stress Obese Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Males female age 2075 year inclusive . Type 2 diabetes Males Females BMI &gt; 30 Subjects statin , ACE inhibitor , thiazolidenediones antioxidant allow long stable dos compound dosage change course study . BP control No change require BP medication HbA1c &gt; 7 % Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week Pregnancy Hepatic disease ( abnormal LFT 's ) , Renal impairment ( serum creatinine &gt; 1.5 ) , Participation concurrent clinical trial Any lifethreatening , noncardiac disease , Uncontrolled hypertension ( BP &gt; 160/100 mm Hg ) Congestive Heart Failure Use investigational agent therapeutic regimen within 30 day study Subjects Exenatide , incretin insulin therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>